Most trials of adjuvant treatment, such as CTONG1104 and EVIDENCE, have found beneficial effects of treatment with EGFR-TKIs plus chemotherapy in patients with resected NSCLC [21, 22]. Here, EGFR is linked to non-small cell lung carcinoma.